OncLive TV

Johannes Schetelig, MD, MSc, discusses data for anti–T-lymphocyte globulin vs post-transplant cyclophosphamide for GVHD prophylaxis in hematologic malignancies.

Mabel Mardones, MD, discusses data for first-line giredestrant plus palbociclib in ER-positive, HER2-negative advanced breast cancer.

Eric Mou, MD, discusses efficacy data for tacabrutideg in chronic lymphocytic leukemia and what these findings may mean for the field.

Lorenzo Falchi, MD, discusses key unmet needs and important next steps for diffuse large B-cell lymphoma research.

Matthew Galsky, MD, discusses the FDA approval of pembrolizumab plus enfortumab vedotin in MIBC.

Daniel Ermann, MD, discusses findings from a real-world study of first-line BTK inhibitors in older patients with chronic lymphocytic leukemia.

Hannah Kenny, MD, and Joseph M. Curry, MD, discuss findings from a phase 2 study of cemiplimab in locally advanced BCC of the head and neck.

Peter E. Fecci, MD, PhD, discusses therapeutic advances and challenges in the management of glioblastoma, and the trajectory of immunotherapy development.

Stephan Stilgenbauer, MD, discusses efficacy data for tacabrutideg from CaDAnCe-101 and how it will inform future CLL research.

Daniel Ermann, MD, discusses data for real-world treatment burdens among older patients with chronic lymphocytic leukemia.

Andrew Ko, MD, details the safety profile of Optune Pax in the PANOVA-3 trial for patients with locally advanced pancreatic cancer.

Daniel Ermann, MD, discusses improvements shown in real-world data for zanubrutinib compared with acalabrutinib in treatment-naive CLL.

Claudio Cerchione, MD, PhD, discusses the significance of the FDA approval of subcutaneous isatuximab in multiple myeloma.

Toni Choueiri, MD, discusses data from LITESPARK-022 in ccRCC.

Elias Jabbour, MD, discusses the significance of the FDA approval of orally disintegrating nilotinib tablets for chronic myeloid leukemia.

Toni Choueiri, MD, discusses how he will utilize adjuvant belzutifan plus pembrolizumab in ccRCC after its FDA approval.

Alexey Danilov, MD, PhD, discusses DAYBreak CLL-201 and how it plans to evaluate bexobrutideg in chronic lymphocytic leukemia.

Matthew S. Davids, MD, MMSc, discusses how efficacy data for pirtobrutinib plus venetoclax and rituximab from BRUIN CLL-322 may affect relapsed/refractory CLL management.

Praful Ravi, MB, BChir, MRCP, discusses the design of the PSMAtrack study of changes in PSMA-PET during initial therapy in patients with mHSPC.

Alan L. Ho, MD, PhD, discusses an upcoming phase 3 trial evaluating Oz-V in OPSCC and key aspects of its design.

Praful Ravi, MB, BChir, MRCP, discusses the clinical utility of PSMA-PET in mHSPC.

Tanios S. Bekaii-Saab, MD, discusses FIGHT-302 data showing frontline pemigatinib significantly improves PFS in FGFR2-positive cholangiocarcinoma.

Praful Ravi, MB, BChir, MRCP, discusses data from the phase 4 PSMAtrack trial in mHSPC.

Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses the potential role for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.

Tanios S. Bekaii-Saab, MD, discusses the clinical significance of the FDA approval of zenocutuzumab for NRG1 fusion–positive CCA.

Nirav N. Shah, MD, MSHP, discusses the design of DAYBreak CLL-201 and its potential importance for chronic lymphocytic leukemia management.

Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses efficacy data for the in vivo CAR T-cell therapy KLN-1010 in multiple myeloma.

Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses key features of in vivo CAR T-cell therapy in multiple myeloma.

Prithviraj Bose, MD, discusses the ongoing investigation of sapablursen in polycythemia vera.

Ruta D. Rao, MD, discusses a prospective sub-study of the PARTNER trial evaluating the effect of ctDNA status on distant recurrence in early TNBC.